The Effect of omega-3 polyunsaturated Fatty Acid Supplements on Microvolt T-Alternans in Patients with Ventricular Arrythmia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002688-10-GB

Enrollment

Unknown

Registered

2005-06-30

Start date

2005-08-31

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Implantable Cardioverter Defibrillator(ICD) with ventricular arrythmias

Interventions

Trade Name: Omacor Product Name: Omega-3 Product Code: PL15905/0001 Pharmaceutical Form: Capsule, soft Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral us

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ICD patients with ventricular arrythmias Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients in atrial fibrillation Frequent atrial or ventricular ectopics ventricular pacing from the ICD unstable angina NYHA 1V heart failure Child bearing age

Design outcomes

Primary

Measure	Time frame
Main Objective: Reduction of microvolt T wave alternans by omega-3 PUFAs;Secondary Objective: None;Primary end point(s): Quantitative and qualitative measures of MTWA during n-3 PUFAs treatment compared to placebo	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026